ALD403 (eptinezumab)

eptinezumab · Alder Biopharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALD403 (eptinezumab), covering 2020-06-09 to 2020-06-09. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine [Phase 3]